Summary & Overview
HCPCS J9295: Injection, necitumumab, 1 mg
HCPCS Level II code J9295 designates necitumumab supplied as an injectable oncology drug and is billed per 1 mg of product. As a drug-specific HCPCS code, J9295 is used by hospitals, physician offices, and infusion centers to report the medication portion of systemic anticancer therapy. Nationally, oncology drug codes like J9295 matter because they drive drug reimbursement, inform utilization tracking, and factor into payer-provider contract negotiations for high-cost biologics.
Key payers included in this analysis are Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for necitumumab, payer coverage considerations, common billing modifiers and service line placement, and benchmark-oriented insights where available. The publication also summarizes coding practices for drug units, typical sites of service for infusion delivery, and areas where payers commonly apply policies such as prior authorization or medical necessity reviews.
This piece is intended to help billing managers, practice administrators, and revenue cycle professionals understand the role of HCPCS Level II code J9295 in oncology drug billing and the payer landscape at a national level. Data not available in the input will be noted where applicable.
Billing Code Overview
HCPCS Level II code J9295 describes the administration unit for necitumumab, billed per 1 mg of the drug. This code represents the drug product itself rather than the administration procedure and is used for oncology infusion billing where necitumumab is furnished as an injectable antineoplastic agent.
Service Type: Injectable drug supply
Typical Site of Service: Hospital outpatient infusion center, physician office infusion suite, or oncology clinic
Clinical & Coding Specifications
Clinical Context
A typical patient is a 65-year-old male with advanced or metastatic squamous non–small cell lung cancer (NSCLC) receiving systemic therapy. Necitumumab (J9295) is administered as an IV infusion in an outpatient oncology infusion center or hospital outpatient department as part of a chemotherapy regimen (commonly combined with platinum-based doublet chemotherapy). The workflow includes order verification by the oncologist, chemotherapy preparation by pharmacy (weight-based or regimen-based dosing converted to mg), pre-medication and allergy assessment by nursing, placement of peripheral IV or use of an implanted port, administration of the necitumumab dose with vital sign monitoring, and post-infusion observation for infusion reactions. Documentation includes the drug name, dose in mg, lot number, date and time of administration, site of service, patient tolerance, and any administered pre-medications or interventions for adverse effects. Billing is submitted using the HCPCS Level II code J9295 reported per milligram as indicated on the vial and in the medical record.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 | No modifier — default reporting | Used when no other modifier applies and service is reported normally. |